Furthermore, CD8+PD1+ T cells were predictive of treatment response.52 In another study, CD8+PD-1+LAG3− T cells assessed on pre-treatment surgical resections were also predictive of ICI response in GC.54 Given these findings, it is pertinent to further investigate whether CD8+ T-cell populations in biopsy specimens could serve as predictive markers for response to neoadjuvant immunotherapy in GC, potentially in combination with PD-1 and PD-L1 assessment.55 This evidence concerns the gene CD274 and gastric cancer.